Broccoli Compound Sulforaphane Shows Preclinical Promise for Friedreich Ataxia
核心洞察
Researchers at Swinburne University of Technology found that sulforaphane, a natural compound in broccoli, can raise levels of frataxin (搜索), the protein deficient in Friedreich ataxia (搜索).
The compound also protected vulnerable nerve cells from damage and affected cellular stress and inflammation in preclinical models.
Friedreich ataxia (搜索) is a rare, incurable genetic disease affecting roughly 200 Australians, with no approved treatments specifically for children.
A naturally occurring compound found in broccoli may offer a new avenue for treating Friedreich ataxia (搜索), a rare and currently incurable inherited disease that progressively damages the nervous system. Researchers at Swinburne University of Technology, led by Associate Professor Faith Kwa, found that sulforaphane can act on several of the biological problems involved in the condition, raising levels of the deficient protein frataxin (搜索) while also protecting vulnerable nerve cells from damage.
Friedreich ataxia (搜索) is a rare genetic condition that mainly affects the brain, spinal cord and nerves. Over time, it can make walking, speaking and carrying out everyday activities increasingly difficult. The disease often begins during childhood or the teenage years, although symptoms can sometimes appear later. Around 200 people in Australia are estimated to live with the condition, making it unfamiliar to much of the public.
The disease is caused by changes in a gene responsible for producing a protein called frataxin (搜索). People with Friedreich ataxia (搜索) do not make enough of this protein, which helps cells manage iron and produce energy properly. When frataxin levels are too low, cells can become damaged by chemical stress and problems with energy production. Nerve cells are particularly vulnerable, helping explain why movement, balance and coordination gradually worsen. The condition can also affect other parts of the body, with some patients developing heart problems, diabetes, hearing loss or changes in vision, and severity can vary considerably between individuals.
There is currently no cure, and treatment largely focuses on managing symptoms and complications. The lack of treatment options is especially difficult for children and their families because the disease can continue to progress for many years. Associate Professor Kwa emphasized that there are currently no approved treatments specifically for children, even though children account for most people affected by the disease.
The Swinburne team investigated sulforaphane, a natural compound found in vegetables such as broccoli and especially associated with broccoli sprouts and other vegetables in the same plant family. The study found that sulforaphane could increase levels of frataxin (搜索), the protein that is deficient in Friedreich ataxia (搜索). It also helped protect vulnerable nerve cells from damage in the researchers' experimental models.
The compound appeared to work on more than one part of the disease process. In addition to improving frataxin (搜索) levels, it affected cellular stress and inflammation, two processes that may contribute to damage in Friedreich ataxia (搜索). The research was published in the journal Antioxidants & Redox Signaling, with the paper titled "Unlocking Sulforaphane's Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons."
"Friedreich ataxia (搜索) is a devastating rare genetic disease that progressively steals a child's ability to walk, speak, play, and ultimately survive," Kwa said. "This novel therapeutic agent can target the underlying cause of the disease, while delivering an affordable and accessible therapy worldwide, improving treatment opportunities for families affected by this life-limiting disease."
One possible advantage of sulforaphane is that scientists already know considerably more about its safety than they would about a completely new drug. Purified forms of the compound are available, and it has previously been studied in both adults and children. "Sulforaphane already has an established safety record in children and adults, and its pure and bioactive form is commercially available. This means if clinical trials prove successful, its rollout could accelerate the path to patient impact," Kwa said.
The researchers are now hoping to secure funding for clinical trials. Such trials would need to test whether the encouraging laboratory findings translate into meaningful improvements in people living with the disease. The rarity of Friedreich ataxia (搜索) creates another challenge, as rare diseases often receive less public attention, and recruiting enough patients for large clinical trials can be difficult, which can slow the development of new treatments.
The study is promising because sulforaphane appears to influence the central protein problem in Friedreich ataxia (搜索) while also protecting cells from other forms of damage. A treatment capable of acting on several disease processes could have advantages over one that addresses only a single effect. Still, these results should be viewed as an early step rather than evidence of a new treatment ready for patients. Clinical studies must establish whether purified sulforaphane reaches the right tissues, improves symptoms or slows disease progression, and remains safe when used at therapeutic doses over time.
The research also should not be interpreted to mean that eating large amounts of broccoli will raise frataxin (搜索) enough to treat Friedreich ataxia (搜索). The amount, preparation and delivery of a medical treatment can be very different from normal dietary exposure. If future trials are successful, however, an already available natural compound could offer an unusually practical path toward treatment for families affected by this life-limiting disease.